로켓 파마슈티컬스(RCKT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.46 (-1.14%), 시가총액 $0.40B, 52주 최저~최고 $2.33 ~ $7.04.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of
로켓 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
로켓 파마슈티컬스의 현재 주가는 $3.46 (-1.14%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
로켓 파마슈티컬스의 시가총액은 약 $0.40B입니다.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and de